ArticleTherapeutic advances in neurological disorders2020
Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.
Article in Therapeutic advances in neurological disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Fertility, pregnancy and lactation in women with systemic lupus erythematosus.Nature reviews. Rheumatology · 2026Review
- Maternal Multiple Sclerosis and Offspring's Developmental and Behavioral Profile: A Case-control Study.Current neuropharmacology · 2026Article
- Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the Global MAPLE-MS Pharmacovigilance Program.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Practical Considerations for Managing Pregnancy in Patients With Multiple Sclerosis: Dispelling the Myths.Neurology. Clinical practice · 2024Review
- Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.Frontiers in neurology · 2023Article
- Maternal Multiple Sclerosis and Offspring's Cognitive and Behavioral Development: What Do We Know until Now?Children (Basel, Switzerland) · 2022Review
- A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.European journal of clinical investigation · 2022Review
- Clinical Features and Maternal-fetal Results of Pregnant Women in COVID-19 Times.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2021Review
- Treatment of Women with Multiple Sclerosis Planning Pregnancy.Current treatment options in neurology · 2021Review
- Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.American journal of obstetrics & gynecology MFM · 2020Review
- Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.Drug safety · 2020Article
- ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2020Article
- The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis.Therapeutic advances in neurological disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe goal of the present cohort study was to review outcomes of patients exposed to interferon beta-1b during pregnancy.
methodsPregnancy cases with exposure to interferon beta-1b reported to Bayer's pharmacovigilance (PV) database from worldwide sources from January 1995 through February 2018 were retrieved for evaluation. Only cases where pregnancy outcomes were unknown at the time of reporting (i.e. prospective cases) were included in the analysis of this retrospective cohort study.
resultsAs of February 2018, 2581 prospective pregnancies exposed to interferon beta-1b were retrieved from the database; 1348 pregnancies had documented outcomes. The majority of outcomes [1106 cases (82.0%)] were live births. Health status was known for 981 live births (no known health status for 125). Most of the prospective pregnancies with known outcomes corresponded to live births with no congenital anomalies [896 cases (91.3%)]. Spontaneous abortion occurred in 160 cases (11.9%). Congenital birth defects were observed in 14/981 live births with known health status [1.4%, 95% confidence interval (CI) 0.78-2.38]. No consistent pattern in the type of birth defect was identified. Rates of both spontaneous abortion and birth defects were not higher than the general population.
conclusionsThese PV data, the largest sample of interferon beta-1b-exposed patients reported to date, suggest no increase in risk of spontaneous abortion or congenital anomalies in women exposed during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.